SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/333242"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/333242" > Are JAKis more effe...

  • Bower, HannahKarolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden. (författare)

Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden.

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • BMJ Publishing Group Ltd,2023

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/333242
  • https://gup.ub.gu.se/publication/333242URI
  • https://doi.org/10.1136/rmdopen-2023-003648DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:154665333URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-521845URI
  • https://lup.lub.lu.se/record/1bef2d41-0240-49ca-b2d8-322ddf8a5416URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • To investigate whether the relative effectiveness of janus kinase inhibitors (JAKis) versus tumour necrosis factor inhibitors (TNFi) or other biological disease-modifying antirheumatic drugs in rheumatoid arthritis differ by the presence or absence of risk factors for cardiovascular (CV) disease, age, sex and smoking.Through Swedish registers, we identified 13493 individuals with 3166 JAKi, 5575 non-TNFi and 11 286 TNFi treatment initiations 2016-2022. All lines of therapy were included, with the majority in second line or higher. Treatment response was defined as the proportion reaching European Alliance of Associations for Rheumatology (EULAR) good response and Clinical Disease Activity Index (CDAI) remission, respectively, within 6 months. Crude percentage point differences in these proportions (JAKis, and non-TNFis, vs TNFis) overall and by risk factors were observed, and adjusted for confounders using linear regression models. Predicted probabilities of response and remission were estimated from adjusted Poisson models, and presented across CV risk and age.Overall, adjusted percentage point differences indicated higher response (+5.0%, 95% CI 2.2% to 7.9%) and remission (+5.8%, 95% CI 3.2% to 8.5%) with JAKis versus TNFis. The adjusted percentage point differences for response in those above 65, at elevated CV risk, and smokers were +5.9% (95% CI 2.7% to 9.0%), +8.3% (95% CI 5.3% to 11.4%) and +6.0% (95% CI 3.3% to 8.7%), respectively. The corresponding estimates for remission were +8.0% (95% CI 5.3% to 10.8%), +5.6% (95% CI 3.0% to 8.2%) and +7.6% (95% CI 5.5% to 9.7%).As used in clinical practice, response and remission at 6 months with JAKis are higher than with TNFi. Among patients with risk factors of concern, effectiveness is similar or numerically further increased. For individualised benefit-to-risk ratios to guide treatment choice, safety and effectiveness in specific patient segments should be considered.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Frisell, ThomasKarolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden. (författare)
  • di Giuseppe, DanielaKarolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden. (författare)
  • Delcoigne, BenedicteKarolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden. (författare)
  • Lindström, UlfGothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Univ Gothenburg, Inst Med, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.,Sahlgrenska Academy(Swepub:lu)bioo-uli (författare)
  • Turesson, CarlLund University,Lunds universitet,Reumatologi,Forskargrupper vid Lunds universitet,Rheumatology,Lund University Research Groups(Swepub:lu)med-ctn (författare)
  • Chatzidionysiou, KaterinaKarolinska Institutet,Karolinska Univ Hosp, Rheumatol Theme Inflammat & Ageing, Stockholm, Sweden.,Karolinska University Hospital (författare)
  • Lindqvist, ElisabetLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups(Swepub:lu)reum-eli (författare)
  • Knight, AnnUppsala University,Uppsala universitet,Reumatologi(Swepub:uu)ankni172 (författare)
  • Forsblad d'Elia, Helena,1961Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine,Institute of Medicine, Department of Rheumatology and Inflammation Research,Univ Gothenburg, Inst Med, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.,Sahlgrenska Academy(Swepub:gu)xforhe (författare)
  • Askling, JohanKarolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.;Karolinska Univ Hosp, Rheumatol Theme Inflammat & Ageing, Stockholm, Sweden.,Karolinska University Hospital (författare)
  • Karolinska InstitutetKarolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:RMD open: BMJ Publishing Group Ltd9:42056-5933

Internetlänk

Hitta via bibliotek

  • RMD open (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy